| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 02/02/2005 | EP1235574B1 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 02/02/2005 | EP1137413B1 Non-peptide antagonists of glp-1 receptor and methods of use |
| 02/02/2005 | EP0847275B1 Regulation of intracellular glucocorticoid concentrations |
| 02/02/2005 | EP0828754B1 Dipeptides which promote release of growth hormone |
| 02/02/2005 | CN1575338A Bv8 nucleic acids and polypeptides with mitogenic activity |
| 02/02/2005 | CN1575191A Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors |
| 02/02/2005 | CN1575182A Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/02/2005 | CN1187369C Method for producing peptide salts. their use, and pharmaceutical prepns. containing these peptide salts |
| 02/02/2005 | CN1187366C New 19-nor-pregene derivatives |
| 02/02/2005 | CN1187326C Novel compounds |
| 02/02/2005 | CN1187325C Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 02/02/2005 | CN1187042C Plaster which contains steroids and its production method and uses |
| 02/01/2005 | US6849710 Method for the synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide |
| 02/01/2005 | US6849653 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| 02/01/2005 | US6849631 Semicarbazides and their uses |
| 02/01/2005 | US6849625 Use in manufacture of a medicament for use as an anti-invasive agent in containment and/or treatment of solid tumor disease |
| 02/01/2005 | CA2083159C The combination of growth hormone and insulin-like growth factor-1 enhances growth |
| 01/27/2005 | WO2005007633A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 01/27/2005 | WO2005007165A1 Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| 01/27/2005 | WO2005007164A1 Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| 01/27/2005 | US20050020676 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents |
| 01/27/2005 | US20050020584 Benzamide derivatives as antagonists of orexin receptors |
| 01/27/2005 | US20050020549 aqueous suspension; rhinitis therapy |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020504 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 01/27/2005 | US20050020494 Modified human growth hormone |
| 01/27/2005 | US20050020489 Use of hcg and lh in controlled ovarian hyperstimulation |
| 01/27/2005 | US20050019908 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 01/27/2005 | US20050019858 Novel human cytokine/steroid receptor protein |
| 01/27/2005 | US20050019854 Analyzing insulin response; solid phase synthesis; for treatment of prediabetes, hyperinsulinemia, and type II diabetes; kits |
| 01/27/2005 | US20050019837 Using glutamate decarboxylase concentration as diagnostic indicator of autoimmune and connective tissue disorders |
| 01/27/2005 | US20050019821 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/27/2005 | US20050019437 Administering a photoestrogen for treating urinary bladder infection and dry vagina; plant extracts is obtained from solvent extraction |
| 01/27/2005 | US20050019408 time-release agents comprising water-swellable matrix cores containing estrogen derivative extracted from animals surrounded by film-forming coatings |
| 01/27/2005 | US20050019367 Continuous release of luteinizing hormone releasing hormone (lh-rh) analogue of leuprorelin, buserelin, triptorelin, and/or goserelin |
| 01/27/2005 | CA2819769A1 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 01/27/2005 | CA2531508A1 Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| 01/27/2005 | CA2531507A1 Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| 01/26/2005 | EP1499721A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription factors |
| 01/26/2005 | EP1499601A1 New 2-substituted -1,3-thiazole compounds |
| 01/26/2005 | EP1499599A1 Substituted pyrazine derivatives |
| 01/26/2005 | EP1499588A1 Melanocortin receptor ligands |
| 01/26/2005 | EP1499578A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| 01/26/2005 | EP1499360A2 Formulation comprising buprenorphine |
| 01/26/2005 | EP1499357A1 Treatment of metabolic syndrome |
| 01/26/2005 | EP1499352A1 Recombinant anti-interleukin-9 antibodies |
| 01/26/2005 | EP1499345A2 Protein a compositions and methods of use |
| 01/26/2005 | EP1499338A1 7-hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof |
| 01/26/2005 | EP1499336A2 Protease inhibitors |
| 01/26/2005 | EP1499322A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy |
| 01/26/2005 | EP1499321A2 Methods for increasing the therapeutic response to electroconvulsive therapy ("ect") |
| 01/26/2005 | EP1499190A2 Methods for treating liver disease and liver damage with growth hormone and foxm1b |
| 01/26/2005 | EP1320359B1 Thermogelling biodegradable aqueous polymer solution |
| 01/26/2005 | EP1301514B1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/26/2005 | EP1296976B1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 01/26/2005 | EP0579758B1 Parathyroid hormone receptor and dna encoding same |
| 01/26/2005 | CN1571782A Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 01/26/2005 | CN1569196A Rhodiola sacra injection and its preparation |
| 01/26/2005 | CN1569195A Rhodiola sacra soft capsule and its preparation |
| 01/26/2005 | CN1569163A Application of drynaria in the treatment of hyperthyroidism and its preparation |
| 01/26/2005 | CN1569064A Novel use of bighead atractylodes rhizome in pharmacy |
| 01/26/2005 | CN1569054A Dripping pills of 'Xiao Chaihu' |
| 01/26/2005 | CN1186332C New thryoid receptor ligands and process II |
| 01/26/2005 | CN1186326C Propane-1, 3-dione derivatives |
| 01/25/2005 | US6846844 (3R)-5-((2-hydroxy-4-methylphenyl)amino)-3-methyl-5-oxo-pentan oic acid, or 3,5-dichloro derivative or salts thereof; deliver active agents to selected biological systems in increased or improved bioavailability |
| 01/25/2005 | US6846824 E.g., ethyl 3-(4-(2-(3-oxo-2H-1,4-benzoxazin-4-yl)ethoxy)-phenyl-2-ethoxypropenoate where 1,4-benzothiazine or quinoxaline can be substituted for the benzoxazine ring; anticholesterol, diabetic agents; obesity; hyperlimpidemia |
| 01/25/2005 | US6846676 In Vivo production and delivery of erythropoietin or insulinotropin for gene therapy |
| 01/25/2005 | CA2123224C Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of t-lymphocytes |
| 01/20/2005 | WO2005005477A2 Stabilised insulin compositions |
| 01/20/2005 | WO2005005452A1 Specific glucocorticosteroid compound having anti- inflammatory activity |
| 01/20/2005 | WO2005005451A1 Specific glucocorticosteroid compound having anti- inflammatory activity |
| 01/20/2005 | WO2005005442A1 Silicon compounds and their use |
| 01/20/2005 | WO2005005390A1 Novel enzyme inhibitor |
| 01/20/2005 | WO2004103941A3 Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents |
| 01/20/2005 | WO2004080467A3 Method of treating and preventing hyperparathyroidism with vitamin d2 or d4 compounds |
| 01/20/2005 | WO2004074345A3 Carbonate esters of polyethylene glycol activated by means of oxalate esters |
| 01/20/2005 | WO2003076443A9 Spiro compounds with npy antagonistic activity |
| 01/20/2005 | US20050014952 Therapy for prostate and breast cancer; benign prostatic hyperplasia, alopecia; eating disorders; |
| 01/20/2005 | US20050014941 Cyanoalkylamino derivatives as protease inhibitors |
| 01/20/2005 | US20050014825 Preparation and use of solidified oils |
| 01/20/2005 | US20050014788 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 01/20/2005 | US20050014781 Ring fused pyrazole derivatives as CRF antagonists |
| 01/20/2005 | US20050014736 Composition comprising progesterone-receptor antagonists and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| 01/20/2005 | US20050014703 Cell differentiation, regeneration of epithelium pancreas cells into insulin producing beta-cells; administrering a peptidyl- peptidase activator |
| 01/20/2005 | US20050014686 Somatostatin analogues |
| 01/20/2005 | US20050014241 Human glucose-6-phosphatase molecules and uses thereof |
| 01/20/2005 | US20050013858 Sustained release formulation; shorter treatment duration; higher tolerance; fungal infections |
| 01/20/2005 | CA2531511A1 Silicon compounds and their use |
| 01/19/2005 | EP1498125A1 Use of compounds having ccr antagonism |
| 01/19/2005 | EP1498121A1 Use of specific cyclolignans |
| 01/19/2005 | EP1497438A1 Means and methods for the production of adenovirus vectors |
| 01/19/2005 | EP1497274A2 Terphenyl derivatives, preparation thereof, compositions containing same |
| 01/19/2005 | EP1497273A2 Hydroxamic acid derivatives |
| 01/19/2005 | EP1497268A2 Nitric oxide donors, compositions and methods of use |
| 01/19/2005 | EP1496940A2 Methods of treating diabetes using pde 11a inhibitors |
| 01/19/2005 | EP1496910A1 Kinase inhibitors |
| 01/19/2005 | EP1496898A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496896A1 Inhibitors of akt activity |
| 01/19/2005 | EP1496865A1 Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations |
| 01/19/2005 | EP1496838A2 Substituted amides |